{"id":"th9507","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Carpal tunnel syndrome"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Edema"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":{"chemblId":"CHEMBL2111290","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TH9507 is a long-acting growth hormone therapeutic that binds to growth hormone receptors to promote anabolic effects, including increased lean body mass, improved metabolism, and enhanced physical function. It is being developed as a treatment for HIV-associated lipodystrophy and other conditions characterized by abnormal fat distribution and metabolic dysfunction.","oneSentence":"TH9507 is a recombinant human growth hormone (hGH) analog designed to stimulate growth and metabolic function in patients with growth hormone deficiency or wasting conditions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:11.716Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-associated lipodystrophy"}]},"trialDetails":[{"nctId":"NCT07481734","phase":"PHASE2","title":"Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis, Hepatic Steatosis","enrollment":120},{"nctId":"NCT02572323","phase":"PHASE2","title":"Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2017-02-15","conditions":"Mild Cognitive Impairment","enrollment":73},{"nctId":"NCT03375788","phase":"PHASE2","title":"Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-01-17","conditions":"Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal","enrollment":51},{"nctId":"NCT03150511","phase":"PHASE2","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-06-01","conditions":"Peripheral Nerve Injuries","enrollment":36},{"nctId":"NCT06554717","phase":"PHASE2","title":"Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-07-07","conditions":"HIV-1-infection, Frailty, Impaired Physical Function","enrollment":100},{"nctId":"NCT03226821","phase":"PHASE4","title":"Body Composition and Adipose Tissue in HIV","status":"COMPLETED","sponsor":"Columbia University","startDate":"2018-02-07","conditions":"HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition","enrollment":5},{"nctId":"NCT00608023","phase":"PHASE3","title":"TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy","status":"COMPLETED","sponsor":"Theratechnologies","startDate":"2007-08","conditions":"Lipodystrophy, HIV Infections","enrollment":263},{"nctId":"NCT03826160","phase":"","title":"Growth Hormone Dynamics and Cardiac Steatosis in HIV","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2019-01-30","conditions":"Human Immunodeficiency Virus, Lipodystrophy, Cardiac Disease","enrollment":23},{"nctId":"NCT01388920","phase":"PHASE2","title":"Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting","status":"TERMINATED","sponsor":"Theratechnologies","startDate":"2011-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":3},{"nctId":"NCT02196831","phase":"NA","title":"Tesamorelin Effects on Liver Fat and Histology in HIV","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2015-07-01","conditions":"Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)","enrollment":61},{"nctId":"NCT02931474","phase":"PHASE2","title":"Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia","status":"WITHDRAWN","sponsor":"National Institute of Nursing Research (NINR)","startDate":"2016-10-06","conditions":"Sleep Disorder, Traumatic Brain Injury","enrollment":""},{"nctId":"NCT02553603","phase":"PHASE1","title":"The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment","status":"COMPLETED","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2017-07-18","conditions":"Mild Cognitive Impairment","enrollment":22},{"nctId":"NCT01591902","phase":"PHASE4","title":"Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®","status":"TERMINATED","sponsor":"Theratechnologies","startDate":"2012-06","conditions":"Diabetic Retinopathy, HIV","enrollment":129},{"nctId":"NCT01579695","phase":"","title":"Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®","status":"TERMINATED","sponsor":"Theratechnologies","startDate":"2013-02","conditions":"HIV","enrollment":391},{"nctId":"NCT00675506","phase":"PHASE2","title":"Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-07","conditions":"Abdominal Obesity, Growth Hormone Deficiency","enrollment":60},{"nctId":"NCT01263717","phase":"NA","title":"Effects of Growth Hormone Releasing Hormone in HIV","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-12","conditions":"HIV, HIV Lipodystrophy","enrollment":54},{"nctId":"NCT01788462","phase":"","title":"Egrifta Replacement and Sleep Disordered Breathing","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2012-05","conditions":"Lipodystrophy","enrollment":""},{"nctId":"NCT01632592","phase":"NA","title":"Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2014-01","conditions":"Abdominal Obesity","enrollment":""},{"nctId":"NCT00795210","phase":"NA","title":"Effects of Short-term Growth Hormone in HIV-infected Patients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-02","conditions":"HIV Lipodystrophy","enrollment":25},{"nctId":"NCT00257712","phase":"PHASE2","title":"SMART: Somatotrophics, Memory, and Aging Research Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-02","conditions":"Aging, Mild Cognitive Impairment","enrollment":151},{"nctId":"NCT02012556","phase":"PHASE1","title":"Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients","status":"COMPLETED","sponsor":"Theratechnologies","startDate":"2008-05","conditions":"HIV","enrollment":18},{"nctId":"NCT00123253","phase":"PHASE3","title":"TH9507 in Patients With HIV-Associated Lipodystrophy","status":"COMPLETED","sponsor":"Theratechnologies","startDate":"2005-06","conditions":"HIV Infections, Lipodystrophy","enrollment":412},{"nctId":"NCT00850564","phase":"NA","title":"Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-02","conditions":"Healthy Volunteers","enrollment":15},{"nctId":"NCT01264497","phase":"PHASE2","title":"Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes","status":"COMPLETED","sponsor":"Theratechnologies","startDate":"2002-02","conditions":"Type 2 Diabetes","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TH9507","genericName":"TH9507","companyName":"Theratechnologies","companyId":"theratechnologies","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TH9507 is a recombinant human growth hormone (hGH) analog designed to stimulate growth and metabolic function in patients with growth hormone deficiency or wasting conditions. Used for HIV-associated lipodystrophy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}